Patient ID: fe2c4e5b-58f3-4db4-9d77-13841dd4040b
Age: 33
Gender: Other
Conditions: Cancer, Hypertension
----------------------------------------
Top Matched Trials:

1. A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
   Location: India
   Score: 55.00
   Inclusion Snippet: Inclusion Criteria:

* Participants must be ≥18 years of age, at the time of signing the informed consent
* Participants with Type 2 Diabetes diagnosed for at least 1 year at the time of screening on ...

2. Pre Operative Trastuzumab in Operable Breast Cancer
   Location: India
   Score: 50.00
   Inclusion Snippet: Inclusion Criteria:a.

1. Female subjects aged 18 years or older.
2. Histologically and/or cytologically confirmed diagnosis of breast cancer. Clinical stages breast cancer: HER2 positive, T1 or T2 or...

3. Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
   Location: India
   Score: 50.00
   Inclusion Snippet: Inclusion Criteria:

1. Signed informed consent form (ICF) must be obtained prior to participation in the study.
2. Adult ≥18 years old at the time of informed consent.
3. Stage IIIB/IIIC (not amenabl...

4. Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
   Location: India
   Score: 50.00
   Inclusion Snippet: Inclusion Criteria:

1. Patient willing and able to sign informed consent and to follow the protocol requirements
2. Female patients aged ≥ 18 years at the time of Screening
3. Patient with Eastern Co...

5. Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
   Location: India
   Score: 50.00
   Inclusion Snippet: Inclusion Criteria:

* Signed informed consent must be obtained prior to participation in the study.
* Male or female participants ≥18 years of age at the screening visit with a confirmed diagnosis of...
